相关实验视频

Updated: Jul 10, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

592

阿斯特拉加卢斯多糖促进自并通过向lncRNA Gm41268/PRLR通路来缓解糖尿病病

Zedong Chen1, Huiyu Liang1, Xianxin Yan1

  • 1School of Traditional Chinese Medicine, Jinan University, Guangzhou, China.

Renal failure
|November 23, 2023
PubMed
概括

阿斯特拉加卢斯多糖 (APS) 通过调节Gm41268/PRLR通路来保护糖尿病病 (DN) 的脏. 这包括增强自和减少纤维化,提供来自中国草药的潜在新疗法.

关键词:
阿斯特拉加勒斯的多糖化物.这是一个LncRNARNA.自自是自的过程.糖尿病性脏病 糖尿病性脏病益生菌受体的受体是益生菌受体.

更多相关视频

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

443
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

836

相关概念视频

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
331